COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #59 of 260
6/16 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Huang et al., Annals of the Rheumatic Diseases 2020:79, 1163-1169, doi:10.1136/annrheumdis-2020-217425 (Peer Reviewed)
Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study
Source   PDF   Share   Tweet
Analysis of 1255 COVID-19 patients in Wuhan Tongji Hospital finding 0.61% with systemic autoimmune diseases, much lower than authors expected (3%–10%). Authors hypothesise that protective factors, such as CQ/HCQ use, reduce hospitalization.

Huang et al., 6/16/2020, retrospective, China, Asia, peer-reviewed, 15 authors.
risk of hospitalization, 80.0% lower, RR 0.20, p < 0.001, treatment 8, control 1247.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.